{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:18:41Z","timestamp":1787318321624,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11102-026-01650-4","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:48:00Z","timestamp":1773654480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Old and new pituitary biomarkers: evidence for sex-specificity"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-9127","authenticated-orcid":false,"given":"J\u00fania R.O.L.","family":"Schweizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"issue":"1","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3343\/alm.2022.42.1.3","volume":"42","author":"K Ghazal","year":"2022","unstructured":"Ghazal K, Brabant S, Prie D, Piketty ML (2022) Hormone immunoassay interference: A 2021 update. Ann Lab Med 42(1):3\u201323","journal-title":"Ann Lab Med"},{"issue":"10","key":"1650_CR2","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1210\/clinem\/dgac381","volume":"107","author":"M Tomkins","year":"2022","unstructured":"Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ (2022) Diagnosis and management of central diabetes insipidus in adults. J Clin Endocrinol Metab 107(10):2701\u20132715","journal-title":"J Clin Endocrinol Metab"},{"key":"1650_CR3","first-page":"22","volume":"13","author":"N Lorde","year":"2023","unstructured":"Lorde N, Elgharably A, Kalaria T (2023) Impact of variation between assays and reference intervals in the diagnosis of endocrine disorders. Diagnostics (Basel) 13:22","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"1650_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41380-022-01719-z","volume":"28","author":"BA Tabak","year":"2023","unstructured":"Tabak BA, Leng G, Szeto A, Parker KJ, Verbalis JG, Ziegler TE et al (2023) Advances in human Oxytocin measurement: challenges and proposed solutions. Mol Psychiatry 28(1):127\u2013140","journal-title":"Mol Psychiatry"},{"issue":"6655","key":"1650_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","volume":"390","author":"M Kuro-o","year":"1997","unstructured":"Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T et al (1997) Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 390(6655):45\u201351","journal-title":"Nature"},{"issue":"3","key":"1650_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1006\/bbrc.1997.8019","volume":"242","author":"Y Matsumura","year":"1998","unstructured":"Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y (1998) Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 242(3):626\u2013630","journal-title":"Biochem Biophys Res Commun"},{"key":"1650_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fendo.2017.00323","volume":"8","author":"GD Dalton","year":"2017","unstructured":"Dalton GD, Xie J, An SW, Huang CL (2017) New insights into the mechanism of action of soluble Klotho. Front Endocrinol (Lausanne) 8:323","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5742","key":"1650_CR8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1126\/science.1112766","volume":"309","author":"H Kurosu","year":"2005","unstructured":"Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P et al (2005) Suppression of aging in mice by the hormone Klotho. Science 309(5742):1829\u20131833","journal-title":"Science"},{"issue":"45","key":"1650_CR9","doi-asserted-by":"publisher","first-page":"38029","DOI":"10.1074\/jbc.M509039200","volume":"280","author":"M Yamamoto","year":"2005","unstructured":"Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H et al (2005) Regulation of oxidative stress by the anti-aging hormone Klotho. J Biol Chem 280(45):38029\u201338034","journal-title":"J Biol Chem"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.abb.2014.06.031","volume":"561","author":"MS Razzaque","year":"2014","unstructured":"Razzaque MS (2014) Bone-kidney axis in systemic phosphate turnover. Arch Biochem Biophys 561:154\u2013158","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"1650_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbrc.2010.06.110","volume":"398","author":"Y Yamazaki","year":"2010","unstructured":"Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y et al (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398(3):513\u2013518","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1650_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/ejendo\/lvaf093","volume":"192","author":"J Schweizer","year":"2025","unstructured":"Schweizer J, Schilbach K, Haenelt M, Gagliardo A, Peters A, Thorand B et al (2025) Soluble alpha klotho-impact of biological variables and reference intervals for adults. Eur J Endocrinol 192(5):631\u2013640","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1650_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11154-024-09881-1","volume":"25","author":"K Schilbach","year":"2024","unstructured":"Schilbach K, Bidlingmaier M (2024) Pitfalls in the lab assessment of hypopituitarism. Rev Endocr Metab Disord 25(3):457\u2013465","journal-title":"Rev Endocr Metab Disord"},{"key":"1650_CR14","doi-asserted-by":"crossref","unstructured":"Pecori Giraldi F, Cassarino MF, Sesta A, Terreni M, Lasio G, Losa M (2020) Sexual dimorphism in cellular and molecular features in human ACTH-Secreting pituitary adenomas. Cancers (Basel) 2020 Mar 13;12(3):669.","DOI":"10.3390\/cancers12030669"},{"issue":"1\u20132","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cccn.2005.01.006","volume":"355","author":"OP Soldin","year":"2005","unstructured":"Soldin OP, Hoffman EG, Waring MA, Soldin SJ (2005) Pediatric reference intervals for FSH, LH, estradiol, T3, free T3, cortisol, and growth hormone on the DPC IMMULITE 1000. Clin Chim Acta 355(1\u20132):205\u2013210","journal-title":"Clin Chim Acta"},{"issue":"5","key":"1650_CR16","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J et al (2014) Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 99(5):1712\u20131721","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1650_CR17","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(5):1526\u20131540","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1650_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2265.2007.02784.x","volume":"66","author":"AC Qureshi","year":"2007","unstructured":"Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, Thomas SM, Carroll PV (2007) The influence of the route of oestrogen administration on serum levels of cortisol-binding Globulin and total cortisol. Clin Endocrinol (Oxf) 66(5):632\u2013635","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1650_CR19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1210\/clinem\/dgad763","volume":"109","author":"N Backlund","year":"2024","unstructured":"Backlund N, Lundstedt S, Tornevi A, Wihlback AC, Olsson T, Dahlqvist P, Brattsand G (2024) Salivary cortisol and cortisone can circumvent confounding effects of oral contraceptives in the short synacthen test. J Clin Endocrinol Metab 109(7):1899\u20131906","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1650_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3343\/alm.2020.40.4.285","volume":"40","author":"G Casals","year":"2020","unstructured":"Casals G, Hanzu FA (2020) Cortisol measurements in cushing\u2019s syndrome: immunoassay or mass spectrometry? Ann Lab Med 40(4):285\u2013296","journal-title":"Ann Lab Med"},{"issue":"1","key":"1650_CR21","doi-asserted-by":"publisher","first-page":"e12724","DOI":"10.1111\/jne.12724","volume":"32","author":"SM Moenter","year":"2020","unstructured":"Moenter SM, Silveira MA, Wang L, Adams C (2020) Central aspects of systemic oestradiol negative- and positive-feedback on the reproductive neuroendocrine system. J Neuroendocrinol 32(1):e12724","journal-title":"J Neuroendocrinol"},{"key":"1650_CR22","doi-asserted-by":"publisher","first-page":"953252","DOI":"10.3389\/fnins.2022.953252","volume":"16","author":"AS Kauffman","year":"2022","unstructured":"Kauffman AS (2022) Neuroendocrine mechanisms underlying Estrogen positive feedback and the LH surge. Front Neurosci 16:953252","journal-title":"Front Neurosci"},{"issue":"3","key":"1650_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ogc.2011.05.004","volume":"38","author":"N Santoro","year":"2011","unstructured":"Santoro N, Randolph JF (2011) Jr. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am 38(3):455\u2013466","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"1","key":"1650_CR24","doi-asserted-by":"publisher","first-page":"21258","DOI":"10.1038\/s41598-020-77871-9","volume":"10","author":"AG Soares","year":"2020","unstructured":"Soares AG, Kilpi F, Fraser A, Nelson SM, Sattar N, Welsh PI et al (2020) Longitudinal changes in reproductive hormones through the menopause transition in the Avon longitudinal study of parents and children (ALSPAC). Sci Rep 10(1):21258","journal-title":"Sci Rep"},{"issue":"4","key":"1650_CR25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523\u20131631","journal-title":"Physiol Rev"},{"key":"1650_CR26","doi-asserted-by":"crossref","unstructured":"Samperi I, Lithgow K, Karavitaki N, Hyperprolactinaemia (2019) J Clin Med 8(12):2203.","DOI":"10.3390\/jcm8122203"},{"issue":"1","key":"1650_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000499694","volume":"109","author":"L Vilar","year":"2019","unstructured":"Vilar L, Vilar CF, Lyra R, Freitas MDC (2019) Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology 109(1):7\u201319","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1650_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/09513599509160444","volume":"9","author":"WG Rossmanith","year":"1995","unstructured":"Rossmanith WG, Hohl B, Luttke B (1995) Stimulated Thyrotropin and prolactin secretion in lactating and non-lactating women. Gynecol Endocrinol 9(3):181\u2013188","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1650_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1479-828X.2011.01321.x","volume":"51","author":"MJ Tanner","year":"2011","unstructured":"Tanner MJ, Hadlow NC, Wardrop R (2011) Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust N Z J Obstet Gynaecol 51(4):321\u2013324","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"3","key":"1650_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C et al (2017) 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27(3):315\u2013389","journal-title":"Thyroid"},{"issue":"10","key":"1650_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(23)00227-9","volume":"11","author":"Y Xu","year":"2023","unstructured":"Xu Y, Derakhshan A, Hysaj O, Wildisen L, Ittermann T, Pingitore A et al (2023) The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. Lancet Diabetes Endocrinol 11(10):743\u2013754","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1650_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.20945\/2359-3997000000192","volume":"63","author":"K Schilbach","year":"2019","unstructured":"Schilbach K, Bidlingmaier M (2019) Laboratory investigations in the diagnosis and follow-up of GH-related disorders. Arch Endocrinol Metab 63(6):618\u2013629","journal-title":"Arch Endocrinol Metab"},{"key":"1650_CR33","doi-asserted-by":"crossref","unstructured":"Schilbach K, Gar C, Lechner A, Nicolay SS, Schwerdt L, Haenelt M et al (2019) Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol. 2019 Jul;181(1):55\u201367.","DOI":"10.1530\/EJE-19-0139"},{"issue":"3","key":"1650_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1507\/endocrj.49.379","volume":"49","author":"I Fukuda","year":"2002","unstructured":"Fukuda I, Hizuka N, Itoh E, Yasumoto K, Ishikawa Y, Murakami Y et al (2002) Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3. Endocr J 49(3):379\u2013386","journal-title":"Endocr J"},{"issue":"5","key":"1650_CR35","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1210\/jc.2013-3060","volume":"99","author":"N Friedrich","year":"2014","unstructured":"Friedrich N, Wolthers OD, Arafat AM, Emeny RT, Spranger J, Roswall J et al (2014) Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab 99(5):1675\u20131686","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1650_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ghir.2008.02.001","volume":"18","author":"EO Machado","year":"2008","unstructured":"Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18(5):389\u2013393","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"1650_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-0029-1239522","volume":"42","author":"PC Elias","year":"2010","unstructured":"Elias PC, Lugao HB, Pereira MC, Machado HR, Castro M, Moreira AC (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42(1):50\u201355","journal-title":"Horm Metab Res"},{"issue":"9","key":"1650_CR38","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","volume":"107","author":"L Maione","year":"2022","unstructured":"Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL et al (2022) IGF-I variability over repeated measures in patients with acromegaly under Long-Acting somatostatin receptor ligands. J Clin Endocrinol Metab 107(9):e3644\u2013e53","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1650_CR39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","volume":"193","author":"I Remba-Shapiro","year":"2025","unstructured":"Remba-Shapiro I, Schweizer J, Moscona-Nissan A, Liebert KJP, Jones PS, Schilbach K et al (2025) Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection. Eur J Endocrinol 193(4):564\u2013573","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1650_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2796.2012.02542.x","volume":"272","author":"L Sze","year":"2012","unstructured":"Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brandle M, Schmid C (2012) Excessively high soluble Klotho in patients with acromegaly. J Intern Med 272(1):93\u201397","journal-title":"J Intern Med"},{"key":"1650_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ygcen.2013.04.024","volume":"188","author":"S Kohler","year":"2013","unstructured":"Kohler S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS et al (2013) Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on safe GH cut-off values? Gen Comp Endocrinol 188:282\u2013287","journal-title":"Gen Comp Endocrinol"},{"issue":"4","key":"1650_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1530\/EJE-12-1045","volume":"168","author":"MC Neidert","year":"2013","unstructured":"Neidert MC, Sze L, Zwimpfer C, Sarnthein J, Seifert B, Frei K et al (2013) Soluble alpha-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur J Endocrinol 168(4):575\u2013583","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1650_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/cen.12385","volume":"80","author":"L Sze","year":"2014","unstructured":"Sze L, Neidert MC, Bernays RL, Zwimpfer C, Wiesli P, Haile SR et al (2014) Gender dependence of serum soluble Klotho in acromegaly. Clin Endocrinol (Oxf) 80(6):869\u2013873","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1650_CR44","first-page":"390","volume":"67","author":"A Jawiarczyk-Przybylowska","year":"2016","unstructured":"Jawiarczyk-Przybylowska A, Halupczok-Zyla J, Bolanowski M (2016) Soluble alpha-Klotho - a new marker of acromegaly? Endokrynol Pol 67(4):390\u2013396","journal-title":"Endokrynol Pol"},{"key":"1650_CR45","doi-asserted-by":"crossref","unstructured":"Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, Jorgensen JOL, van der Lely AJ et al (2020) Soluble klotho: a possible predictor of quality of life in acromegaly patients. Endocrine. 2020 Jul;69(1):165\u2013174.","DOI":"10.1007\/s12020-020-02306-4"},{"key":"1650_CR46","doi-asserted-by":"crossref","unstructured":"Schweizer J, Schilbach K, Haenelt M, Giannetti AV, Bizzi MF, Soares BS et al (2021) Soluble alpha Klotho in acromegaly: comparison to traditional markers of disease activity. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e2887\u2013e2899.","DOI":"10.1210\/clinem\/dgab257"},{"key":"1650_CR47","doi-asserted-by":"crossref","unstructured":"Schweizer JROL, Schilbach K, Vogel F, St\u00fcfchen I, V\u00f6lter F, Nowak E, Gagliardo A, Zopp S, Haenelt M, St\u00f6rmann S, Schopohl S, Ribeiro de Oliveira Jr. A, Drummond JB, Reincke M, Bidlingmaier M (2025) Elevated soluble alpha klotho concentrations are specific to active acromegaly among pituitary adenomas. Eur J Endocrinol 193","DOI":"10.1093\/ejendo\/lvaf168.012"},{"issue":"3","key":"1650_CR48","doi-asserted-by":"publisher","first-page":"E326","DOI":"10.1152\/ajpendo.00090.2014","volume":"307","author":"S Shahmoon","year":"2014","unstructured":"Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T (2014) The aging suppressor klotho: a potential regulator of growth hormone secretion. Am J Physiol Endocrinol Metab 307(3):E326\u2013E334","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"1650_CR49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/cen.12756","volume":"83","author":"R Locher","year":"2015","unstructured":"Locher R, Egger A, Zwimpfer C, Sze L, Schmid C, Christ E (2015) Effect of growth hormone replacement therapy on soluble Klotho in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 83(4):593\u2013595","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1650_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-15-1018","volume":"174","author":"A Efthymiadou","year":"2016","unstructured":"Efthymiadou A, Kritikou D, Mantagos S, Chrysis D (2016) The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children. Eur J Endocrinol 174(4):473\u2013479","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1650_CR51","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.metabol.2016.08.004","volume":"65","author":"T Rubinek","year":"2016","unstructured":"Rubinek T, Shahmoon S, Shabtay-Orbach A, Ben Ami M, Levy-Shraga Y, Mazor-Aronovitch K et al (2016) Klotho response to treatment with growth hormone and the role of IGF-I as a mediator. Metabolism 65(11):1597\u20131604","journal-title":"Metabolism"},{"issue":"6","key":"1650_CR52","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40618-022-01757-y","volume":"45","author":"V Guarnotta","year":"2022","unstructured":"Guarnotta V, Pizzolanti G, Petrancosta R, Radellini S, Baiamonte C, Giordano C (2022) Gender-specific soluble alpha-klotho levels as marker of GH deficiency in children: a case-control study. J Endocrinol Invest 45(6):1247\u20131254","journal-title":"J Endocrinol Invest"},{"key":"1650_CR53","first-page":"P660","volume":"81","author":"JROL Schweizer","year":"2022","unstructured":"Schweizer JROL, Schilbach K, Haenelt M, Gagliardo A, St\u00f6rmann S, Schopohl J, Bidlingmaier M (2022) Soluble alpha Klotho in adult patients with growth hormone deficiency. Endocr Abstracts 81:P660","journal-title":"Endocr Abstracts"},{"key":"1650_CR54","first-page":"P527","volume":"99","author":"JROL Schweizer","year":"2024","unstructured":"Schweizer JROL, Schilbach K, Tausendfreund O, Haenelt M, Gagliardo A, Schopohl J, Drey M, Bidlingmaier M (2024) Soluble alpha Klotho concentrations are resistant to short-term stimulation and suppression of growth hormone. Endocr Abstracts 99:P527","journal-title":"Endocr Abstracts"},{"issue":"6","key":"1650_CR55","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1210\/jc.2014-4507","volume":"100","author":"K Timper","year":"2015","unstructured":"Timper K, Fenske W, Kuhn F, Frech N, Arici B, Rutishauser J et al (2015) Diagnostic accuracy of copeptin in the differential diagnosis of the Polyuria-polydipsia syndrome: A prospective multicenter study. J Clin Endocrinol Metab 100(6):2268\u20132274","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1650_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1803760","volume":"379","author":"W Fenske","year":"2018","unstructured":"Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J et al (2018) A Copeptin-Based approach in the diagnosis of diabetes insipidus. N Engl J Med 379(5):428\u2013439","journal-title":"N Engl J Med"},{"key":"1650_CR57","doi-asserted-by":"publisher","first-page":"w20237","DOI":"10.4414\/smw.2020.20237","volume":"150","author":"J Refardt","year":"2020","unstructured":"Refardt J, Christ-Crain M (2020) Copeptin-based diagnosis of diabetes insipidus. Swiss Med Wkly 150:w20237","journal-title":"Swiss Med Wkly"},{"issue":"10198","key":"1650_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0140-6736(19)31255-3","volume":"394","author":"B Winzeler","year":"2019","unstructured":"Winzeler B, Cesana-Nigro N, Refardt J, Vogt DR, Imber C, Morin B et al (2019) Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 394(10198):587\u2013595","journal-title":"Lancet"},{"key":"1650_CR59","doi-asserted-by":"crossref","unstructured":"Khattri Bhandari S, Fan SL, Copeptin as a marker for vasopressin dysregulation and diagnosis. J Appl Lab Med 2026 Jan 5;11(1):143\u2013154.","DOI":"10.1093\/jalm\/jfaf153"},{"key":"1650_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.psyneuen.2019.05.018","volume":"107","author":"EL MacLean","year":"2019","unstructured":"MacLean EL, Wilson SR, Martin WL, Davis JM, Nazarloo HP, Carter CS (2019) Challenges for measuring oxytocin: the blind men and the elephant? Psychoneuroendocrinology 107:225\u2013231","journal-title":"Psychoneuroendocrinology"},{"key":"1650_CR61","doi-asserted-by":"publisher","first-page":"31693","DOI":"10.1038\/srep31693","volume":"6","author":"OK Brandtzaeg","year":"2016","unstructured":"Brandtzaeg OK, Johnsen E, Roberg-Larsen H, Seip KF, MacLean EL, Gesquiere LR et al (2016) Proteomics tools reveal startlingly high amounts of Oxytocin in plasma and serum. Sci Rep 6:31693","journal-title":"Sci Rep"},{"key":"1650_CR62","doi-asserted-by":"publisher","first-page":"889154","DOI":"10.3389\/fchem.2022.889154","volume":"10","author":"A Hering","year":"2022","unstructured":"Hering A, Jieu B, Jones A, Muttenthaler M (2022) Approaches to improve the quantitation of Oxytocin in human serum by mass spectrometry. Front Chem 10:889154","journal-title":"Front Chem"},{"issue":"7","key":"1650_CR63","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","volume":"11","author":"C Atila","year":"2023","unstructured":"Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N et al (2023) Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol 11(7):454\u2013464","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1650_CR64","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ejendo\/lvaf078","volume":"192","author":"C Atila","year":"2025","unstructured":"Atila C, Nikaj A, Leibnitz S, Liechti ME, Christ-Crain M (2025) Neurophysin I: a reliable, novel, and robust biomarker for Oxytocin. Eur J Endocrinol 192(4):502\u2013510","journal-title":"Eur J Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01650-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:04:36Z","timestamp":1779282276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01650-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of interest: KS received speaker\u2019s honoraria and consulting fees by from Novo Nordisk, Pfizer, Recordati Rare Disease, Ipsen, Crinetics, Ascendis Pharma, Camurus, and Pharmanovia. Not related to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}